Skip to main content
Log in

Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock

Frontiers of Medicine Aims and scope Submit manuscript

Abstract

Mantle cell lymphoma is an aggressive subtype of B cell non-Hodgkin lymphoma. It can progress to leukemic phase but frank leukemic picture at initial presentation is not common. Leukemic phase indicates advance stage of the disease and generally associated with extensive extra-nodal involvement. Pericardial invasion has been reported, however we could not find a report of myocardial infiltration by this disease since the appraisal of the term “mantle cell lymphoma” in 1992. Here we report a case of cardiac involvement by mantle cell leukemia leading to cardiogenic shock which complicates the treatment decisions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Banks PM, Chan J, Cleary ML, Delsol G, Wolf-Peeters CD, Gatter K, Grogan TM, Harris NL, Isaacson PG, Jaffe ES, Mason D, Pileri S, Ralfikiaer E, Stein H, Warnke RA. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992; 16(7): 637–640

    Article  CAS  PubMed  Google Scholar 

  2. Shivdasani RA, Hess JL, Skarin AT, Pinkus GS. Intermediate lymphocytic lymphoma: clinical and pathologic features of a recently characterized subtype of non-Hodgkin’s lymphoma. J Clin Oncol 1993; 11(4): 802–111

    CAS  PubMed  Google Scholar 

  3. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999; 36(2): 115–127

    CAS  PubMed  Google Scholar 

  4. Armitage J. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997; 89(11): 3909–3918

    Google Scholar 

  5. Pittaluga S, Bijnens L, Teodorovic I, Hagenbeek A, Meerwaldt JH, Somers R, Thomas J, Noordijk EM, De Wolf-Peeters C. Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the Working Formulation. Blood 1996; 87(10): 4358–4367

    CAS  PubMed  Google Scholar 

  6. Kauh J, Baidas SM, Ozdemirli M, Cheson BD. Mantle cell lymphoma: clinicopathologic features and treatments. Oncology (Williston Park, NY) 2003; 17(6): 879–891, 896; discussion 896–898

    Google Scholar 

  7. Bigoni R, Negrini M, Veronese ML, Cuneo A, Castoldi GL, Croce CM. Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization. Oncogene 1996; 13(4): 797–802

    CAS  PubMed  Google Scholar 

  8. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89(6): 2067–2078

    CAS  PubMed  Google Scholar 

  9. Samaha H, Dumontet C, Ketterer N, Moullet I, Thieblemont C, Bouafia F, Callet-Bauchu E, Felman P, Berger F, Salles G, Coiffier B. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998; 12(8): 1281–1287

    Article  CAS  PubMed  Google Scholar 

  10. Parry-Jones N, Matutes E, Morilla R, Brito-Babapulle V, Wotherspoon A, Swansbury GJ, Catovsky D. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH. Br J Haematol 2007; 137(2): 117–124

    Article  CAS  PubMed  Google Scholar 

  11. Ferry JA. Extranodal lymphoma. Arch Pathol Lab Med 2008; 132(4): 565–578

    PubMed  Google Scholar 

  12. Ambinder AJ, Shenoy PJ, Nastoupil LJ, Flowers CR. Using primary site as a predictor of survival in mantle cell lymphoma. Cancer 2013; 119(8): 1570–1577

    Article  PubMed  Google Scholar 

  13. Bertini M, Rus C, Freilone R, Botto B, Calvi R, Novero D, Orsucci L, Vitolo U, Palestro G, Resegotti L. Mantle cell lymphoma: a retrospective study on 27 patients. Clinical features and natural history. Haematologica 1998; 83(4): 312–316

    CAS  PubMed  Google Scholar 

  14. Bernard M, Gressin R, Lefrère F, Drénou B, Branger B, Caulet-Maugendre S, Tass P, Brousse N, Valensi F, Milpied N, Voilat L, Sadoun A, Ghandour C, Hunault M, Leloup R, Mannone L, Hermine O, Lamy T. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 2001; 15(11): 1785–1791

    Article  CAS  PubMed  Google Scholar 

  15. Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Gutiérrez G, Mercadal S, Campo E, Rozman C, López-Guillermo A, Montserrat E. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008; 19(1): 135–141

    Article  CAS  PubMed  Google Scholar 

  16. Eve HE, Furtado MV, Hamon MD, Rule SA. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol 2009; 27(32): e189–e190, author reply e191

    Article  PubMed  Google Scholar 

  17. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27(8): 1209–1213

    Article  PubMed  Google Scholar 

  18. Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Léger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005; 16(10): 1675–1682

    Article  CAS  PubMed  Google Scholar 

  19. Ghielmini M, Schmitz SFH, Cogliatti S, Bertoni F, Waltzer U, Fey MF, Betticher DC, Schefer H, Pichert G, Stahel R, Ketterer N, Bargetzi M, Cerny T; Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23(4): 705–711

    Article  CAS  PubMed  Google Scholar 

  20. Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99(9): 706–714

    Article  CAS  PubMed  Google Scholar 

  21. Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol 2012; 5(1): 64

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012; 1(1): 36

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin’s lymphoma. Semin Oncol 2002; 29(2 Suppl 6): 18–22

    Article  CAS  PubMed  Google Scholar 

  24. Zhao J, Xu Z, Liu D, Lu Q. Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting. Cancer Cell Int 2012; 12(1): 38

    Article  PubMed Central  PubMed  Google Scholar 

  25. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood 2009; 114(8): 1469–1476

    Article  CAS  PubMed  Google Scholar 

  26. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381(9873): 1203–1210

    Article  CAS  PubMed  Google Scholar 

  27. Jacobson CA, Freedman AS. First-line treatment of indolent lymphoma: axing CHOP? Lancet 2013; 381(9873): 1163–1165

    Article  PubMed  Google Scholar 

  28. Lu K, Wang X. Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol 2012; 5(1): 55

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol 2013; 6:27

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Wu M, Akinleye A, Zhu X. Novel agents for chronic lymphocytic leukemia. J Hematol Oncol 2013;6:36

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Zhao Y, Huang H, Wei G. Novel agents and biomarkers for acute lymphoid leukemia. J Hematol Oncol 2013;6:40

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369(6): 507–516

    Article  CAS  PubMed  Google Scholar 

  33. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O’Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369(1): 32–42

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 2013; 6:59

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Delong Liu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Furqan, M., Chen, Y., Akinleye, A. et al. Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock. Front. Med. 8, 254–258 (2014). https://doi.org/10.1007/s11684-014-0319-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-014-0319-1

Keywords

Navigation